Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Fáze 2, otevřená studie k vyhodnocení bezpečnosti a snášenlivosti progerininu u Wernerova syndromu

30. září 2026 aktualizováno: PRG Science & Technology Co., Ltd.

Otevřená studie fáze 2 k vyhodnocení bezpečnosti a snášenlivosti progerininu pro léčbu ztráty kostní minerální denzity (BMD) u subjektů s typickým Wernerovým syndromem

This is a Phase 2, open-label study to A Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin for the Treatment of Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome.

There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year.

Přehled studie

Postavení

Nábor

Podmínky

Intervence / Léčba

Detailní popis

Subjects who have successfully completed the Screening phase will enter the baseline and treatment phase of the study. Subjects will take the assigned treatment of Progerinin (2400 mg) split as 1200 mg BID in the morning and evening with food for 1-Year.

To evaluate the safety and tolerability of Progerinin for the treatment of BMD loss in subjects with typical Werner syndrome.

The secondary objectives of this study are:

  • To characterize the activity of Progerinin on bone metabolism in subjects with typical Werner Syndrome.
  • To evaluate vascular function in subjects with typical Werner Syndrome.
  • To evaluate glucose metabolism and insulin resistance in subjects with typical Werner Syndrome.
  • To evaluate lipid metabolism in subjects with typical Werner Syndrome.
  • To evaluate physical function in subjects with typical Werner Syndrome.
  • To evaluate the pharmacokinetics (PK) of Progerinin sachet administered twice daily (BID) in subjects with typical Werner Syndrome.

Typ studie

Intervenční

Zápis (Odhadovaný)

5

Fáze

  • Fáze 2

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

    • Michigan
      • Ann Arbor, Michigan, Spojené státy, 48109
        • Nábor
        • University of Michigan

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

[Inclusion Criteria]

  1. Subjects must be at least ≥ 18 years of age.

  2. Subjects should have a confirmed diagnosis of typical Werner syndrome by genetic analysis.

  3. Subjects should be osteopenic (T-score between -1.0 and -2.5) or have confirmed osteoporosis (T-score ≤ -2.5) at screening/baseline. Subjects may continue to receive bone supplements (e.g., bisphosphonates, calcium supplements, Vitamin D supplements, etc.) as appropriate per standard of care throughout the study.

  4. Male or non-pregnant, non-lactating female.

  5. Subjects screening blood chemistry inclusive of metabolic panel, hematology, and urine analysis results should be acceptable to the investigator.

  6. Negative pregnancy test for female subjects as described below. Women of child bearing potential (WOCBP) and Women not of child-bearing potential are eligible to participate. Both women of childbearing potential and women of non-child-bearing potential should use an approved method of birth control and agrees to continue to use this method for the duration of the study and for 90 days after last treatment.

    Acceptable methods of contraception include abstinence, female subject/partner's use of hormonal contraceptive (oral, implanted, or injected) in conjunction with a barrier method (WOCBP only), female subject/partner's use of an intrauterine device (IUD), or if the female subject/partner is surgically sterile or two years post-menopausal. All male subjects/partners must agree to use a In addition, subjects may not donate sperm for the duration of the study and for 90 days after last treatment.

    Females who are less than two (2) years post-menopausal, those with tubal ligations and those using contraception must have a negative serum pregnancy test at baseline within the one (1) week prior to the first study medication administration. Every six weeks, and at study termination a pregnancy test should be performed, either serum or urine stick test. However, if the urine result is positive, a serum pregnancy test will be performed.

  7. Provide signed written informed consent and willingness, ability to comply with study requirements.

  8. Subject must have a projected life expectancy of ≥ 12 months in the opinion of the Investigator.

[Exclusion Criteria]

  1. Subject with clinical signs seen at screening are at the final stage of Werner syndrome progression, and completion of the study is difficult to be assessed, including:

    • Subjects who received continuous or intermittent home oxygen therapy for 6 months before obtaining consent
    • Subjects who received at least 2 hospitalizations for pneumonia during the 12 months prior to obtaining consent
    • Subjects who have at least 10% net weight loss and have not recovered. This includes significant net weight loss over the last six months.
  2. Subjects with significant dehydration as judged by the principal investigator.

  3. Subjects with pericardial fluid, ascites and pleural effusion.

  4. Therapy with investigational drugs within 30 days of beginning study medication.

  5. History of prior malignancy, except for adequately treated in situ cancer, basal cell, squamous cell skin cancer, or other cancers (e.g., breast, prostate) for which the subject has been disease-free for at least 3 years.

  6. Any serious medical condition, laboratory abnormality, psychiatric illness, or comorbidity that, in the judgment of the Investigator, would make the subject inappropriate for the study.

  7. Serious systemic fungal, bacterial, viral, or other infection that is not controlled or requires intravenous (IV) treatment for infection(s).

  8. Subjects with known history of having Acquired Immunodeficiency Syndrome (AIDS) or with a history known to be infected with Human Immunodeficiency Virus (HIV).

  9. Subjects with a history of serious drug hypersensitivity or allergic reaction such as anaphylaxis or any component of the formulation.

  10. Clinically significant bleeding within 2 weeks prior to baseline (e.g., gastrointestinal [GI] bleeding, intracranial hemorrhage).

  11. Medical or recreational use of marijuana or THC-containing compounds within 3 months of screening visit and for the duration of the trial.

  12. Pregnant or lactating women.

  13. Major surgery, defined as any surgical procedure that involves general anesthesia and a significant incision (i.e., larger than what is required for placement of central venous access, percutaneous feeding tube, or biopsy), within 28 days prior to baseline or anticipated surgery during the study period.

  14. Inability to return for scheduled treatment and assessments.

  15. Subjects that require concomitant use of any medications or substances that are strong inhibitors or inducers of CYP2D6 or CYP2C8

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: N/A
  • Intervenční model: Přiřazení jedné skupiny
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Treatment Group

all subjects will receive Progerinin 2400mg (1200mg twice daily) after morning and evening meals for a year

This is a Phase 2, open-label study to evaluate the safety and Tolerability of Progerinin for the treatment of BMD Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome.

. There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year. This study will have three phases: Screening Phase, Treatment Phase, and Follow-Up Phase.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)
Časové okno: Baseline to Week 56 (including 4-week follow-up)

The intensity of the event will be graded using CTCAE v6.0 criteria

Baseline to Week 56 (including 4-week follow-up)
Incidence of Treatment-Related Adverse Events
Časové okno: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Incidence of Serious Adverse Events (SAEs)
Časové okno: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Incidence of TEAEs and SAEs leading to discontinuation of study medication
Časové okno: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Blood Chemistry from Baseline
Časové okno: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Hematology from Baseline
Časové okno: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Urinalysis Results from Baseline
Časové okno: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Height (cm) from Baseline
Časové okno: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Weight (kg) from baseline
Časové okno: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Temperature (°C) from baseline
Časové okno: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Pulse Rate (beats per minute) from baseline
Časové okno: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Respiratory Rate (breaths per minute) from baseline
Časové okno: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Systolic Blood pressure (mmHg) from baseline
Časové okno: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Diastolic Blood pressure (mmHg) from baseline
Časové okno: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Physical Examination findings from baseline
Časové okno: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Change in ECG Ventricular Rate (beats per minute) from baseline
Časové okno: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Change in ECG PR interval (msec) from baseline
Časové okno: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Change in ECG QRS interval (msec) from baseline
Časové okno: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Change in ECG QT interval (msec) from baseline
Časové okno: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Change in ECG QTc interval (msec) from baseline
Časové okno: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)

Sekundární výstupní opatření

Měření výsledku
Časové okno
Change in Femur Bone Mineral Density (BMD) from baseline
Časové okno: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Lumbar Spine BMD from baseline
Časové okno: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Aortic Pulse Wave Velocity (m/s) from baseline
Časové okno: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Insulin Resistance by Oral Glucose Tolerance Test (OGTT) from baseline
Časové okno: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Lipid Profile from baseline
Časové okno: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Handgrip Strength Test from baseline
Časové okno: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Short Physical Performance Battery (SPPB) Total Score from baseline
Časové okno: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Ankle-Brachial Pressure Index (ABPI) from baseline
Časové okno: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Bone-Specific Alkaline Phosphatase (BAP) from baseline
Časové okno: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Osteocalcin (OC) from baseline
Časové okno: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Procollagen Peptides (P1NP) from baseline
Časové okno: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Deoxypyridinium (DPD) from baseline
Časové okno: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in C-Terminal Telopeptide of Type 1 Collagen (CTX) from baseline
Časové okno: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Pharmacokinetic Parameters of Progerinin at the Specified PK Assessment Visits
Časové okno: Baseline, Week12, Week 24, Week 36 and Week 52
Baseline, Week12, Week 24, Week 36 and Week 52

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. října 2026

Primární dokončení (Odhadovaný)

1. prosince 2027

Dokončení studie (Odhadovaný)

1. prosince 2027

Termíny zápisu do studia

První předloženo

31. března 2023

První předloženo, které splnilo kritéria kontroly kvality

26. dubna 2023

První zveřejněno (Aktuální)

6. května 2023

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

5. října 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

30. září 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • PRG-PRO-004

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .